ESB-1609
/ Escape Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 16, 2023
A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5.
(PubMed, Clin Pharmacol Drug Dev)
- "ESB1609 crosses the blood-brain barrier with CSF:plasma ratios ranging between 0.04% and 0.07% across dose levels. ESB1609 demonstrated a favorable safety and tolerability profile at exposures expected to be efficacious."
Journal • P1 data • CNS Disorders
September 14, 2020
ESCAPE Bio Closes $73 Million in Crossover Financing to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration
(Businesswire)
- "ESCAPE Bio...today announced the closing of a $73M financing led by Wellington Management Company LLP....'The proceeds allow us to accelerate two programs into patients who lack disease modifying treatments.'"
Financing • CNS Disorders • Parkinson's Disease
1 to 2
Of
2
Go to page
1